Back to top

HOPEHIV Open Label Prevention Extension – An open-label follow-on trial to ASPIRE in which former ASPIRE participants are offered the opportunity to use the dapivirine ring (there is no placebo) in the context of a study. HOPE will build on the results of ASPIRE by gathering additional information on the ring’s safety, how women use the ring knowing that it can help reduce their risk of HIV and the relationship between adherence and HIV protection. The study also seeks to understand why the ring may work well as an HIV prevention strategy for some women but not for others. For this reason, former participants may enroll in HOPE even if they do not wish to use the ring. HOPE began in July 2016 and is expected to be completed late 2018.



Women’s use of vaginal ring is higher in open-label study, as is level of HIV protection






Next steps and planned studies of the dapivirine vaginal ring



HOPE open-label study of vaginal ring for preventing HIV begins for former ASPIRE participants



See Also

MTN-025 Protocol